What is the recommended management for a 33‑year‑old woman with atypical squamous cells of undetermined significance (ASCUS) and a negative high‑risk human papillomavirus (HPV) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of ASCUS with Negative HPV in a 33-Year-Old Woman

Return to routine screening with co-testing in 3 years. 1

Primary Recommendation

For a 33-year-old woman with ASCUS and negative high-risk HPV testing, no immediate colposcopy or accelerated follow-up is needed; she should return to routine screening intervals. 1, 2 The combination of ASCUS cytology with a negative HPV test places her at very low risk for high-grade cervical intraepithelial neoplasia (CIN 3+), comparable to women with completely normal screening results. 2, 3, 4

Evidence-Based Rationale

  • The ASCCP consensus guidelines (updated 2014) specifically state that HPV-negative ASCUS results have a 5-year CIN3+ risk of only 0.48%, which is closer to the risk after a negative Pap test alone (0.31%) than after negative co-testing (0.11%). 3

  • Women with HPV-negative ASCUS have only a 1.4% risk of developing CIN 3 or worse during 2-year follow-up, compared to 15.2% for HPV-positive ASCUS women. 4

  • The negative predictive value for CIN3+ after HPV-negative ASCUS approaches 99.7-100%, making immediate colposcopy unnecessary overtreatment. 2, 4

Specific Follow-Up Protocol

Schedule repeat co-testing (Pap + HPV) in 3 years, not 5 years. 1 This is a critical update from earlier guidelines:

  • The 2012 ASCCP consensus initially recommended 5-year follow-up for HPV-negative ASCUS, but updated data from the Kaiser Permanente Northern California cohort showed that cancer risk remained disproportionately elevated despite low dysplasia risk. 1

  • The current recommendation is co-testing at 3 years rather than 5 years for HPV-negative ASCUS in women aged 30-65. 1

  • If co-testing is unavailable, repeat Pap testing alone in 3 years is acceptable. 1

Age-Specific Considerations

  • At age 33, this patient falls into the 30-65 age group where co-testing is the preferred screening strategy. 1

  • Co-testing every 5 years is preferred for routine screening in this age group, but the presence of a prior ASCUS result (even with negative HPV) warrants the shorter 3-year interval. 1

  • HPV testing is appropriate for women ≥25 years with ASCUS for triage purposes, unlike younger women where HPV prevalence is high and often transient. 1

What NOT to Do: Common Pitfalls

  • Do not perform repeat HPV testing before 12 months from the initial negative result, as this leads to unnecessary testing and potential false-positive results. 2

  • Do not refer for immediate colposcopy, as the negative predictive value of HPV-negative ASCUS is 99.7-100% for CIN3+. 2, 4

  • Do not use the 5-year interval that applies to completely negative co-testing; HPV-negative ASCUS requires the 3-year interval. 1

  • Do not perform HPV 16/18 genotyping, as it does not alter management for ASCUS results and the patient is already HPV-negative. 1

  • Do not allow this patient to exit screening at age 65 based solely on this HPV-negative ASCUS result; she will need 2 consecutive negative co-tests or 3 consecutive negative Pap tests before discontinuing screening. 1

Alternative Management if Co-Testing Unavailable

If HPV testing is not available for follow-up:

  • Repeat Pap testing alone in 12 months is acceptable. 2
  • If that repeat Pap shows ASCUS or worse, refer for colposcopy. 2
  • If negative, continue routine 3-year Pap screening. 1

Documentation and Patient Education

  • Document that the patient had ASCUS with negative high-risk HPV testing at age 33. 2

  • Counsel the patient that her current risk is very low but she must return for screening in 3 years (not 5 years) due to the prior ASCUS finding. 1

  • Emphasize that this 3-year interval applies even though her HPV test was negative, as updated guidelines recognize a slightly elevated long-term cancer risk. 1, 3

Related Questions

What is the appropriate management for a 30‑year‑old woman with a satisfactory Pap test lacking an endocervical/transformation‑zone component, atypical squamous cells of undetermined significance (ASC‑US), negative high‑risk human papillomavirus (HPV) mRNA, and Candida infection?
What is the recommended follow-up for a patient with atypical squamous cells of undetermined significance (ASC-US) and negative Human Papillomavirus (HPV) testing?
What is the next step for a 42-year-old patient with an Atypical Squamous Cells of Undetermined Significance (ASCUS) result on their Pap (Papanicolaou) smear who is Human Papillomavirus (HPV) negative?
When should a 48-year-old woman with a prior atypical squamous cells of undetermined significance (ASC-US) Pap result and HPV-negative test four years ago have her next Pap test?
What is the next step for a 59-year-old female with a Pap result showing Atypical Squamous Cells of Undetermined Significance (ASC-US) and a negative Human Papillomavirus (HPV) test?
Why should tirzepatide (Mounjaro) not be co‑administered with sitagliptin (Januvia)?
Is it appropriate to give vancomycin, azithromycin (Zithromax) and ceftriaxone (Rocephin) for pneumonia?
What medication can be added to treat clinically significant agitation in an older adult with dementia?
How should I manage diarrhea in an 80-year-old patient?
What is the most reliable non‑invasive scan to diagnose cardiac amyloidosis in an older adult with unexplained left‑ventricular wall thickening, heart‑failure symptoms, and low‑voltage ECG?
Patient prescribed clonidine 0.1 mg three times daily (TID) as needed (PRN) for 7 days was mistakenly dispensed a glipizide 2.5 mg/metformin 250 mg combination tablet; what steps should be taken to correct the dispensing error and manage possible hypoglycemia and uncontrolled hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.